Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425101 | 0.85 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL31038926 | 0.84 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL18188096 | 0.84 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL2429629 | 0.84 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL31038919 | 0.83 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL2430468 | 0.83 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL31038846 | 0.83 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL15809068 | 0.82 | HSD17B10 (0.35) | DGAT1 | |
| SCHEMBL2428934 | 0.82 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL24211029 | 0.81 | ADRA2A (0.44) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552799-B2 | Triazolone compounds | NXERA PHARMA UK LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| EP-4654964-A1 | SULFONE-1H-PYRROLE-2-CARBOXAMIDE INHIBITORS OF SARS-COV-2 NSP14 METHYLTRANSFERASE AND DERIVATIVES THEREOF | The Rockefeller University (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | RAPPORT THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | RAPPORT THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| CN-115867550-B | Triazolone compounds | 奈克斯拉制药英国有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-12145934-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-19 | — | — | US | disclosed |
| US-12139485-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-12 | — | — | US | disclosed |
| WO-2024158875-A1 | SULFONE-1H-PYRROLE-2-CARBOXAMIDE INHIBITORS OF SARS-COV-2 NSP14 METHYLTRANSFERASE AND DERIVATIVES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 2024-08-02 | — | — | WO | disclosed |
| EP-4126871-B1 | TRIAZOLONE COMPOUNDS | HEPTARES THERAPEUTICS LTD (GB) | 2024-05-08 | — | — | EP | disclosed |
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ASTRAZENECA AB (SE) | 2023-05-11 | — | — | US | disclosed |
| EP-3288940-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016176460-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | disclosed |
| EP-2205590-B1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-06-04 | — | — | EP | disclosed |
| US-8629137-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629137-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629137-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20130029975-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130029975-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20110059954-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059954-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059954-A1 | CGRP ANTAGONISTS | CALCRL, CALCR, CALCA | DGAT1 3971/4885 |
| US-20230146796-A1 | TRIAZOLONE COMPOUNDS | ADORA2A, ADORA1, ADORA3 | DGAT1 2656/4885 |
| US-12139485-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | DGAT1 4396/4885 |
| US-12145934-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | DGAT1 4396/4885 |
| US-20130029975-A1 | CGRP ANTAGONISTS | CALCRL, CALCR, CALCA | DGAT1 3971/4885 |
| US-12552799-B2 | Triazolone compounds | ADORA1, ADRA2C, ADORA2A | DGAT1 2549/4885 |
| US-12304908-B2 | Azabenzimidazoles and their use as AMPA receptor modulators | GRIN1, GRIN2B, GRIN3A | DGAT1 4396/4885 |
| US-20250230157-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | DGAT1 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.